Worapol Ngamcherdtrakul
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2017First federal award
$10.1MFederal grants as PI15 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
15 awards · $10.1M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 23, 2025 | NIH | SBIR Phase II PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer | $1.3M | PDX PHARMACEUTICALS, INC. |
| Aug 29, 2024 | NIH | SBIR Phase II PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer | $914K | PDX PHARMACEUTICALS, INC. |
| Dec 8, 2023 | NIH | SBIR Phase II Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer | $933K | PDX PHARMACEUTICALS, INC. |
| Jul 6, 2023 | NIH | SBIR Phase II PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer | $400K | PDX PHARMACEUTICALS, INC. |
| Dec 1, 2022 | NIH | SBIR Phase II Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer | $933K | PDX PHARMACEUTICALS, INC. |
| Aug 19, 2022 | NIH | SBIR Phase II In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune Response | $102K | PDX PHARMACEUTICALS, INC. |
| Sep 23, 2021 | NIH | SBIR Phase II Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer | $378K | PDX PHARMACEUTICALS, INC. |
| Sep 1, 2021 | NIH | SBIR Phase II In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune Response | $2.0M | PDX PHARMACEUTICALS, INC. |
| Jan 29, 2020 | NIH | SBIR Phase II Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer | $513K | PDX PHARMACEUTICALS, INC. |
| May 22, 2019 | NIH | SBIR Phase II Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer | $234K | PDX PHARMACEUTICALS, INC. |
| Apr 15, 2019 | NIH | SBIR Phase II Supplement grant for R44CA217534: Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer | $15K | PDX PHARMACEUTICALS, INC. |
| Jun 1, 2018 | NIH | SBIR Phase II Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer | $1.5M | PDX PHARMACEUTICALS, INC. |
| Aug 15, 2017 | NIH | SBIR Phase I Development of topical formulation of siRNA nanoparticle for treating skin diseases | $325K | PDX PHARMACEUTICALS, INC. |
| Aug 11, 2017 | NIH | SBIR Phase I Development of topical formulation of siRNA-nanoparticle for treating skin diseases | $325K | PDX PHARMACEUTICALS, INC. |
| May 16, 2017 | NIH | SBIR Phase II Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer | $225K | PDX PHARMACEUTICALS, INC. |
Peer ranks
Federal funding#60
Awards as PI#46
Patents#273
Companies
- PDX PHARMACEUTICALS, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.